novo nordisk semaglutide mash leads therapeutic race Novo Nordisk's Wegovy Gets SEC
Description
Will GLP-1s remain dominant, or will new innovations emerge
See PA requirements, how to get approved, and what to do if denied.
Request a quote today!
Altimmune just made a big move in the world of GLP-1 research, but this time, its not about obesity.The company announced yesterday that it has officially begun enrolling participants in a Phase 2 trial of pemvidutide, its GLP-1 and glucagon dual receptor agonist, to evaluate the drug in people with Alcohol Use Disorder, or AUD
